



PRESS RELEASE

Woke Imports Psilocybin from Purisys in the US for Formulation of Novel Dosage Forms

- Successful import of psilocybin material from Purisys in the US to Australia
- Partnership with IDT Australia ensured efficient import and customs clearance
- Supports ongoing formulation work with Monash MMIC for novel low- and high-dose forms
- Maintains trajectory to commence Phase IIB trials for depression in 2022

03 February 2022 – Woke Pharmaceuticals Pty Ltd ('Woke' or 'the Company'), a Sydney NSW-based company focused on psychedelics for mental health, is pleased to announce that it has successfully imported its first order of synthetic psilocybin from Purisys LLC ('Purisys') for the formulation of novel dosage forms to treat depression.

Purisys is based in Athens, Georgia, specialising in the synthetic manufacture of Active Pharmaceutical Ingredients (APIs), including psychedelic drugs. The company has a United States Drug Enforcement Agency (DEA) licensed and FDA-inspected manufacturing facility with the required quality assurance and quality control to support Woke's supply chain needs.

Woke's importation and warehousing partner, IDT Australia (ASX: IDT), has the relevant licenses from the Office of Drug Control and Victoria's Department of Health and Human Services for Schedule 9 products, including psilocybin. Under these licences and those of Woke's formulation partner, Monash University's Medicines Manufacturing Innovation Centre, the successful import of material maintains Woke's development timelines.

Woke is developing two novel dosage forms of psilocybin for the treatment of depression. Both candidates are expected to commence Phase IIB trials this year. The first is WP001, a novel low-dose (1mg – 5mg) rapid release capsule of psilocybin for the treatment of moderate depression. The second novel clinical candidate, WP002, is a high dose (25mg) tablet with concomitant psychotherapy, for treatment-resistant depression.

Mr Nick Woolf, CEO of Woke Pharmaceuticals, said: "We have established an effective supply chain for the import of synthetic psilocybin to support Woke's R&D plan, thanks to the licences and proven track-record of our partners. The successful import of material is aligned with our formulation, manufacturing, and clinical plans. Psychedelics such as psilocybin have the potential to address unmet medical needs and benefit patients with depression as well as other mental health disorders. We anticipate commencing clinical trials later this year."

ENDS

This announcement was authorised for release by the Directors of Woke Pharmaceuticals.

For more information, please contact:

Mr Nick Woolf
CEO
info@wokeph.com
+61 417 986 005



PRESS RELEASE

ABOUT WOKE PHARMACEUTICALS

Woke Pharmaceuticals Pty Ltd is an Australian-based company focused on the development and commercialisation of novel psychedelic therapies for the treatment of mental health disorders. The Company's lead candidates are based on synthetic psilocybin for the treatment of depression. Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi. Clinical trials have shown its safety and efficacy in the treatment of depression and other disorders. Woke Pharmaceuticals is developing a novel micro-dose formulation for treatment of moderate depression and a novel high-dose formulation with concomitant psychotherapy for treatment of major depression. Both candidates are expected to enter Phase II trials in 2022 with leading investigators in the field of mental health. For further information, please visit www.wokeph.com.

IDT Australia Limited (ASX: IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.

Purisys LLC Headquartered in Athens, Georgia, USA Purisys is a leading provider of API contract manufacturing and development services including custom synthesis and analytical development services for clinical stage compounds. Purisys' expertise includes extensive scientific and regulatory know-how, state-of-the-art manufacturing technologies and a track record of delivering projects on time. Purisys can develop a broad range of APIs including clinical stage compounds used to treat a variety of indications including therapeutic areas such as cardiovascular, central nervous system, mental health, and oncological drugs. The company has a long-term, successful regulatory track record in the pharmaceutical industry with a commitment to high purity, consistency, and compliance. Purisys also has a comprehensive set of CDMO offerings and a robust reference standard program to support the pharmaceutical industry's delivery of innovative new therapies to patients.